Clinical trials: Hepatic Chemotherapy
Hepatocellular Carcinoma, Lenvatinib
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor, Hepatic Arterial Infusion Chemotherapy
- Trial name
- NCT06333561
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Liver Metastases, Recurrent Colon Cancer
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well giving combination chemotherapy and bevacizumab before surgery and radiolabeled monoclonal antibody therapy works in treating liver metastases in patients with metastatic colorectal cancer.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer
- Trial name
- NCT01320683
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma
HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large and unresectable hepatocellular…
- Trial name
- NCT03048123
- Testing
- Hepatic arterial infusion, Transarterial chemoembolization, Folfox Protocol
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world and causes death of about 600000~1000000 people each year.
- Trial name
- SOON (NCT01997957)
- Testing
- S-1
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu
Breast Cancer, eHealth
Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects
Chemotherapy induces side effects varying in severity, impacting patients' quality of life and necessitating unplanned hospital care. Patient-reported outcomes (PROs) could aid in early detection and management of side effects.
- Conditions
- Breast Cancer, eHealth, Symptom Monitoring, Self Management
- Trial name
- eChemoCoach (NCT06424054)
- Testing
- eChemoCoach
- Volunteers
- 746 people
- Sponsor
- Noordwest Ziekenhuisgroep
Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage
A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)
This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Bevacizumab and Sintilimab (Triplet-combined Therapy) for Unresectable A-staged Hepatocellular Carcinoma in…
- Trial name
- NCT05214339
- Testing
- Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT05121571
- Testing
- HAIC, Sorafenib
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma, Carcinoma
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
The purpose of this study is to evaluate the efficacy of sorafenib in combination with low dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.
- Conditions
- Advanced Hepatocellular Carcinoma, Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms
- Trial name
- NCT01214343
- Testing
- Sorafenib with Low-dose FP, Sorafenib
- Where
- 30 sites in Japan
- Volunteers
- 190 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Advanced Solid Tumors, Relapsed/Refractory Lymphoma
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
The purpose of this study is to evaluate the effect of moderate or severe hepatic impairment on the single-dose pharmacokinetics of alisertib in adult participants with cancer.
- Trial name
- NCT02214147
- Testing
- Alisertib
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
This single-center, prospective, single-arm Phase II clinical trial is designed to evaluate the efficacy and safety of combining hepatic artery infusion chemotherapy (HAIC, for up to 4 cycles) with iparomlimab/tuvonralimab plus…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
- Trial name
- NCT07062055
- Testing
- Anti-VEGF, Immunotherapy, Local Therapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shandong Cancer Hospital and Institute
Sinusoidal Obstruction Syndrome, Colorectal Liver Metastases
Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants
The purpose of the study is to determine whether anticoagulant use (i.e. salicylates, clopidogrel, low-molecular weight heparin, or coumarin derivates) is able to prevent the development of the sinusoidal obstruction syndrome…
- Trial name
- NCT00885950
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
HCC - Hepatocellular Carcinoma
HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure
For patients with advanced liver cancer who have progressed after first-line targeted and immunotherapy , there is currently no standard treatment regimen for second-line therapy.
- Trial name
- NCT06375317
- Testing
- PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets
- Volunteers
- 42 people
- Sponsor
- Yehua Shen
Bile Duct Neoplasms, Colorectal Neoplasms
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
Due to discontinuation of the Codman C3000 pump, an alternate device is necessary to continue serving patients in need of hepatic arterial infusion chemotherapy.
- Trial name
- NCT04276090
- Testing
- Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter., Hepatic artery infusion pump floxuridine and dexamethasone, Systemic chemotherapy for colorectal liver metastases
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Michael J Cavnar, MD
Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
The goal of this observational study is to evaluate whether hepatic artery infusion pump (HAIP) chemotherapy can improve outcomes in patients with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant…
- Conditions
- Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma, Duodenal Cancer, Duodenal Adenocarcinoma
- Trial name
- NCT07845617
- Testing
- Hepatic Artery Infusion Pump (HAIP), Floxuridine (FUDR)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- AdventHealth
Hepatocellular Carcinoma
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Although resection provided survival benefit for selected HCC patients with PVTT, the recurrence rate is still high for those patients.
- Trial name
- NCT06031285
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Hepatic Impairment, Healthy Volunteers
A Study of TAK-279 in Adults With or Without Liver Damage
The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with liver problems compared to participants without liver problems.
- Trial name
- NCT05976321
- Testing
- TAK-279
- Where
- 4 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Takeda
Intrahepatic Bile Duct Cancer, Intrahepatic Cholangiocarcinoma (Icc)
Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery
The goal of this clinical trial is to learn if additional chemotherapy by means of a chemo pump can prevent return of disease in adult patients with bile duct cancer in the liver that can be treated with surgery.
- Conditions
- Intrahepatic Bile Duct Cancer, Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma
- Trial name
- PUMP IV (NCT06888063)
- Testing
- Hepatic Arterial Infusion Pump chemotherapy with floxuridin
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Erasmus Medical Center
Colorectal Cancer, Liver Metastases
Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure
Standard treatment of metastatic colorectal cancers relies on fluoropyrimidines, irinotecan alone or in association with fluoropyrimidines, oxaliplatin in association with fluoropyrimidines, bevacizumab and anti EGFR antibodies.
- Trial name
- HEARTO (NCT01348412)
- Testing
- oxaliplatin, raltitrexed, other intravenous chemotherapy drugs
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Centre Georges Francois Leclerc
Hepatecellular Carcinoma, Liver Injury
HAIC vs. TACE Combined With ICIs and TKIs in Intermediate-to-Advanced HCC: A Multicenter Study on Liver Injury and Survival
The purpose of this study is to compare the liver injury induced by HAIC combined with PD-1/PD-L1 inhibitors and TKIs versus triple therapy with TACE in the treatment of patients with advanced HCC; to compare the efficacy of the…
- Conditions
- Hepatecellular Carcinoma, Liver Injury, HAIC(Hepatic Artery Infusion Chemotherapy), TACE(Transcatheter Arterial Chemoembolization)
- Trial name
- NCT07277192
- Where
- China
- Volunteers
- 562 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma
Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma
To evaluate safety and efficacy of combined hepatic arterial infusion (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT02981498
- Testing
- Hepatic arterial infusion chemotherapy, Folfox Protocol
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University